Rivulet Media Inc (fka RIVU)

[stervc]

Significance of BMSN IND & Breast Cancer Treatment News…

Significant for understanding, read the post/link below:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84957802

... HemaXellerate I™ is eligible for Orphan Drug designation where from such, there is a 70% chance that the FDA will give an accelerated approval. Even before then, there is an 85% chance that Investigational New Drug (IND) applications gets approved.

Below is some key info to help investors to understand the importance of this breast cancer treatment news (also looks like their drug will be used to treat prostate cancer too). Within this post, you will be able to see how this news ”potentially” positions BMSN to be able to make billions of dollars per year just from this breast cancer piece alone.

Please, don’t just believe me. Read through this post and do the math yourself.

Below are some links to confirm that there is basically around 220,000+ new cases of breast cancer in the US and 1,300,000+ new cases of breast cancer worldwide that are diagnosed. One could also Google this data to research to see that such is correctly and vastly considered:
http://www.cdc.gov/cancer/breast/statistics/
http://globocan.iarc.fr/factsheets/cancers/breast.asp
http://www.cancerresearchuk.org/cancer-info/cancerstats/world/breast-cancer-world/

This is very significant and very powerful with understanding this recent news from BMSN’s wholly owned subsidiary Regen BioPharma, Inc. positioning itself to own the patented intellectual property covering a novel means of treating breast cancer by augmenting the immune system using a "gene silencing" approach.

As per the PR…
http://ih.advfn.com/p.php?pid=nmona&article=56463068

Provenge is a vaccine for prostate cancer that costs $93,000 per treatment cycle(1) and had sales of $240 million in the last three quarters of 2012, despite only increasing survival by 4.1 months(2). Dendreon's Provenge requires extraction of dendritic cells, a "master cell" of the immune system, and manipulation outside of the body. The technology developed by Professor Min involves "training" of the same dendritic cells inside of the body by administration of specific nanoparticles. Proof of concept of these nanoparticles were published by Professor Min in collaboration with University of California San Diego in the prestigious scientific journal Blood (Zheng et al. Blood. 2009 Mar 19;113(12):2646-54). …

For inquiring minds, Dendreon Corp. trades under the ticker of DNDN on the NASDAQ GS at $5.70+ per share:
http://finance.yahoo.com/q?s=DNDN

If Dendreon’s cancer vaccine/medicine called Provenge that has already been approved by the FDA costs $93,000 per treatment and is considered the best thing out there now for fighting cancer and can generate Revenues of $240,000,000 for just three quarters, then BMSN’s technique for its own cancer medicine under their "gene silencing" approach that’s considered 100% times better can be sold for at least the same $93,000 per treatment or higher upon FDA approval in my opinion which could generate far more in Revenues.

As I had indicated above, there are basically around 220,000+ new cases of breast cancer in the US and 1,300,000+ new cases of breast cancer worldwide that are diagnosed.

Potential Annual Revenues within the US:
220,000 US New Cases x $93,000 per treatment = $20,460,000,000

Potential Annual Revenues within the World:
1,300,000 Worldwide New Cases x $93,000 per treatment = $120,900,000,000

With keeping things real, please understand that it is not likely that BMSN would treat everyone within the world although the potential to consider such exists. So I would not expect those numbers above although a few billion still would not be out of the question considering that their treatment would apply to a few other types of cancer treatments too.

A more conservative number would be to know that BMSN probably would only be able to treat somewhere in the area of 3,500 patients per year from researching the norm for some other companies on the major market in a fairly perfect world. This means that a more conservative number would be as indicated below…

Potential Annual Revenues from probable amount to receive cancer treatment:
3,500 Probable Amount Treated x $93,000 per treatment = $325,500,000

As you can see, this is in line with what some of the major market stocks/companies are generating from the sale of their treatments. Still, the potential is there to make well above that amount when you start considering treatment for prostate cancer and other cancers.

As stated from this news, which confirms the validity of their approach, this gene silencing therapy was developed through over 1.5 million dollars of grant funding at the University of Western Ontario, Canada. This approach offers the possibility of destroying tumors in a non-toxic manner through leveraging the body's own immune system to recognize the cancer as "foreign" and subsequently eradicating it.
http://ih.advfn.com/p.php?pid=nmona&article=56463068

About Dr. Weiping Min, M.D. (BMSN's expert on this treatment0:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85035901
http://regenbiopharma.com/advisory-board.html

v/r
Sterling